NUBEQA® (darolutamide) | mCSPC and nmCRPC Treatment Option | HCP NUBEQA® (darolutamide) is an FDA-approved prescription treatment for mCSPC for use with or without docetaxel and nmCRPC See safety and full prescribing Info Learn more about NUBEQA® (darolutamide) on the official physician website
Dosing Information | NUBEQA® (darolutamide) | HCP - Nubeqa HCP US FTP . . . NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA
Treatment Guidelines | NUBEQA® (darolutamide) | HCP - Nubeqa HCP US . . . NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA
mCSPC Efficacy | NUBEQA® (darolutamide) | HCP - Nubeqa HCP US FTP Label Explore efficacy, study design, and adverse reactions from the ARASENS and ARANOTE trials of NUBEQA® (darolutamide) in mCSPC See safety and full prescribing Info See the ARANOTE and ARASENS clinical study efficacy results of NUBEQA® (darolutamide)
Access Services by Bayer | NUBEQA® (darolutamide) | HCP NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA
mCSPC Safety | NUBEQA® (darolutamide) | HCP - Nubeqa HCP US FTP Label Concomitant use of NUBEQA with a combined P-gp and strong CYP3A4 inhibitor increases darolutamide exposure which may increase the risk of NUBEQA adverse reactions Monitor patients more frequently for NUBEQA adverse reactions and modify NUBEQA dosage as needed
DDI Profile | NUBEQA® (darolutamide) | HCP - Nubeqa HCP US FTP Label NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA
For Your Patients | NUBEQA® (darolutamide) | HCP - Nubeqa HCP US FTP Label NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA